Publications in collaboration with researchers from Instituto de Investigación Sanitaria de Navarra (43)

2025

  1. Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial(Nature Medicine, 10.1038/s41591-023-02347-y)

    Nature Medicine

  2. Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors

    Molecular Cancer, Vol. 24, Núm. 1

  3. Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas

    Cell Reports Medicine, Vol. 6, Núm. 7

  4. Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters

    Human Gene Therapy

  5. Translational advancement of immunotherapeutics against pediatric central nervous system tumors

    Advances in Cancer Research

  6. Virus Against Cancer: Paradigm-Shifting Biological Concepts

    Current Neurology and Neuroscience Reports, Vol. 25, Núm. 1

2024

  1. Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry

    STAR Protocols, Vol. 5, Núm. 1

  2. Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models

    JCI Insight, Vol. 9, Núm. 18

  3. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

    Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737

  4. The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles

    Molecular Therapy Oncology, Vol. 32, Núm. 2

  5. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

    Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525

2023

  1. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393

  2. Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson's disease

    GLIA, Vol. 71, Núm. 3, pp. 571-587

  3. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378

  4. Oncolytic virotherapy for the treatment of pediatric brainstem gliomas

    Revue Neurologique, Vol. 179, Núm. 5, pp. 475-480

  5. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 169-188

  6. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2022

  1. DNA-damaging cancer cells to improve virotherapy

    Molecular Therapy - Oncolytics

  2. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas

    JCI Insight, Vol. 7, Núm. 7

  3. Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 26, pp. 246-264